Answers are grounded in this paper and cite their sources.
Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) provide substantial glycemic and cardiometabolic benefits, but concerns regarding diabetic retinopathy (DR) progression and nonarteritic anterior ischemic optic neuropathy (NAION) have raised questions about their ocular safety. This review critically evaluates current evidence and its clinical implications. Methods A structured literature search of PubMed/MEDLINE, Embase, and Scopus was conducted from inception through July 2026. Evidence from randomized trials, observational studies, meta‐analyses, pharmacovigilance investigations, clinical guidelines, and regulatory documents was narratively synthesized. Results In SUSTAIN‐6, semaglutide increased DR complications compared with placebo (3.0% vs. 1.8%; hazard ratio 1.76, 95% confidence interval 1.11–2.78), predominantly among patients with pre‐existing retinopathy and substantial early glycemic improvement. However, subsequent trials and meta‐analyses did not establish a consistent class‐wide increase in retinopathy risk. Early worsening appears more closely associated with rapid glycemic reduction than with established direct retinal toxicity. Observational and pharmacovigilance studies have identified a potential association between GLP‐1 RAs and NAION, although conflicting findings, limited event numbers, and residual confounding preclude definitive causal inference. Conclusions Current evidence favors individualized ocular risk assessment and targeted ophthalmologic surveillance rather than routine avoidance of GLP‐1 RAs. Patients with established retinopathy warrant particular attention during treatment initiation. Prospective studies incorporating standardized ophthalmologic outcomes are essential to clarify unresolved safety signals and optimize clinical monitoring.
No takes yet. Share an insight, caveat, or question.
Hanna et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: